Photographer: Simon Dawson/Bloomberg

Roche Breast Cancer Drug Fails to Win U.K. Backing

  • U.K. cost adviser says evidence of long-term benefits needed
  • Perjeta costs at least $10,500 depending on treatment cycles

Roche Holding AG’s Perjeta treatment for breast cancer failed to win the backing of the U.K.’s health-cost adviser, the latest salvo in an ongoing struggle between Britain and the world’s biggest maker of cancer medicines over prices.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.